Plain-English translation of NCT06343038 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new radioactive treatment called 161Tb-SibuDAB for men with advanced prostate cancer that has stopped responding to standard treatments. The medication uses a special type of radioactive particle designed to deliver higher doses of radiation directly to cancer cells while sparing healthy tissue. Researchers believe this approach may work better than the current standard radioactive treatment for this type of cancer.
About one-third of patients with this type of prostate cancer do not respond well to the current standard radioactive treatment, even though their tumors are visible on imaging. Scientists think the new treatment delivers stronger doses of radiation to both large tumors and tiny cancer spots throughout the body, which could help patients whose cancer has become resistant to existing therapies.
You likely qualify if…
You likely don't qualify if…
Depending on which group you are assigned to, you will receive injections of the new medication and/or the standard treatment, with a 3-week waiting period between them to let the first dose clear your body. Some participants will receive four cycles of treatment with the new medication over several months, with safety and effectiveness checks after each cycle. Throughout the study, you will have regular blood tests, imaging scans, and clinic visits to monitor how the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Switzerland